MedAI Verdict

AI Medical Billing · 46 tools

Editorial illustration: a clinical chart note feeding into ICD-10 / CPT code rows, with a clean claim emerging on the right.

AKASA

AKASA logo
31/ 100

Evidence & Documentation Score

This legacy score reflects documented evidence, integrations, transparency, and market signals. It does not measure overall product performance. A new product-focused rating system is in development. How it is computed

reviewed November 2, 2026

Vendor
AKASA, US
Pricing
No public price.
EHR
Not stated
Compliance
HIPAA, SOC 2, NIST 800-53 +1 more

Bottom line. AKASA sells revenue cycle AI to hospitals, and on October 2, 2026 it launched what it calls autonomous coding for inpatient charts. The vendor claims 500 hospitals as customers, while a RevCycleAI profile dated August 25, 2026 lists no disclosed customer count, and sources disagree on headquarters and funding. Outside evidence is one short KLAS report built on a single… Read the full bottom line

Visit AKASA (opens in new tab)

HIPAA · SOC 2 · NIST 800-53 · CIS

Performance profile

  • Regulatory and compliance10 / 10
  • Clinical integration0 / 31.4
  • Evidence strength0 / 10
  • Vendor and market8.4 / 12
  • Sentiment and transparency3.3 / 6.5

Performance profile

  • Regulatory and compliance10 / 10
  • Clinical integration0 / 31.4
  • Evidence strength0 / 10
  • Vendor and market8.4 / 12
  • Sentiment and transparency3.3 / 6.5
On this page

All 8 dimensions

Regulatory and compliance

  • HIPAA / SOC2 / BAA10 / 10

    HIPAA + (SOC2 or BAA) attested

Clinical integration

  • EHR integrations (count)0 / 18.2

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0 / 8

    None of the top-3 EHRs covered

  • Bidirectional write-back0 / 5.2

    No bidirectional write-back documented

Evidence strength

  • Peer-reviewed papers0 / 7

    No peer-reviewed paper evaluating the product

  • RCT / meta-analysis / systematic review0 / 3

    No RCT, meta-analysis, or systematic review evaluating the product

Vendor and market

  • Funding & adoption signal8.4 / 12

    Mid-tier funding and adoption

Sentiment and transparency

  • Pricing transparency3.3 / 6.5

    Pricing on request, no public amounts

Computed November 6, 2026 by our public rubric. How it’s computed

What it costs

From
No public price.
Price points
1
Verified
November 2, 2026
Source
Vendor pricing page

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

Compliance

Attested
HIPAA, SOC 2, NIST 800-53, CIS
EHR integrations
Not stated
FDA
Not stated

Carries HIPAA, SOC 2, NIST 800-53, CIS per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Vendor stability

Company
AKASA
Headquarters
US
Founded
Not stated

Vendor sitewww.akasa.com (opens in new tab)

Evidence record

RecordWhat we found
Verification
  • Score computed November 6, 2026, method 1.2.1
  • Review written November 2, 2026
Cite this record

MedAI Verdict, AKASA record, https://medaiverdict.com/tools/akasa, version November 2, 2026

Change historyView every change to this record

Bottom line

AKASA sells revenue cycle AI to hospitals, and on October 2, 2026 it launched what it calls autonomous coding for inpatient charts. The vendor claims 500 hospitals as customers, while a RevCycleAI profile dated August 25, 2026 lists no disclosed customer count, and sources disagree on headquarters and funding. Outside evidence is one short KLAS report built on a single early adopter, plus that RevCycleAI profile, which calls AKASA "promising but unproven". Inpatient coding teams at health systems are the buyers. Outpatient facility coding is described only as coming, so outpatient-focused groups have little to assess yet.

Autonomous inpatient coding and revenue cycle AI for health systems.

No public price. HIPAA + SOC 2 Type II attested.

What did the October launch add?

The vendor describes an autonomous mid-cycle platform for inpatient coding and clinical documentation improvement. Its press release says the coding product "reads and reasons across the complete patient record" with evidence behind every code. The homepage describes a custom model for each health system, with the customer setting the autonomy threshold. The release also claims that coding which takes a human 30 to 60 minutes per inpatient encounter finishes in under 90 seconds after discharge.

The wider suite, per the homepage, includes a prebill optimization suite pairing coding and CDI, a CDI assistant, a research assistant and automation for authorization and claim status.

How many hospitals use it?

The homepage says 500 hospitals in all 50 states, representing one in ten US inpatient discharges. The press release adds more than $180 billion in aggregate net patient revenue and inpatient volume up almost 6x in a year. Named customers are Cleveland Clinic, which uses prebill review and "intends to explore" autonomous coding, and Nebraska Methodist Health System. The release quotes its CFO, Jeff Francis, crediting improved revenue integrity, denials, write-offs and payment speed.

Where is AKASA based, and what has it raised?

The press release is datelined South San Francisco, while aggregators say San Francisco. Aggregators give 2018 as the founding year and Alpha Health as the earlier name, and list four co-founders including CEO Malinka Walaliyadde. The About page names no founders and no year.

Totals disagree by source. Aggregators put funding at about $205M across four rounds, including a $60M Series B led by Andreessen Horowitz on March 23, 2021. The $120M Series C is dated June 2024 by some sources and February 2022 by PitchBook, and Tracxn shows only $85M in all.

What backs the accuracy claims?

The vendor says "third-party, blinded evaluations" covering 65% to 85% of inpatient volume found its AI matched or exceeded human coders on MS-DRG, principal diagnosis, quality capture and present-on-admission indicators. Evaluator and sample are not named. KLAS published a short report on April 1, 2026 based on one early adopter, and a KLAS blog says it lacks enough feedback on vendors other than CodaMetrix, Fathom and Nym.

RevCycleAI lists limited independent validation, lengthy implementation, payer-portal fragility and few referenceable clients among AKASA's weaknesses.

What does the platform page state?

It says AKASA integrates with clinical data repositories through APIs, EDI or other means and names no EHR. It claims HIPAA-compliant infrastructure and "SOC 2, NIST-800-53, and CIS certified", without a SOC 2 type. No price is public.

The verdict

AKASA fits a health system with inpatient coding volume that wants autonomous coding configured to its own autonomy threshold. Outpatient facility coding has nothing yet beyond the vendor's "soon".

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

Link to this review

AKASA, reviewed on MedAI Verdict

Vendors may place this badge on their own site. It links to this review with a tracking parameter and has no effect on the score.

<a href="https://medaiverdict.com/tools/akasa?utm_source=vendor_badge&utm_medium=badge&utm_campaign=akasa"><img src="https://medaiverdict.com/badges/reviewed-on-medaiverdict.png" srcset="https://medaiverdict.com/badges/reviewed-on-medaiverdict@2x.png 2x" alt="AKASA, reviewed on MedAI Verdict" width="200" height="56"></a>

What we have not verified

  1. We have not run AKASA in our own clinical practice. Pricing, certifications, and EHR-integration claims come from vendor documentation and have not been independently audited.
  2. Enterprise pricing tiers and SLA terms are typically under NDA and not publicly verifiable. Numbers shown reflect publicly disclosed self-service or list pricing only.
  3. Real-world latency, note quality, and accuracy in your specific specialty and patient population can vary materially from vendor demonstrations. We recommend a 30-day trial with two providers before commitment.

Last verified . Read our methodology · Billing & coding